Family Management Corp increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.8% during the second quarter, Holdings Channel.com reports. The fund owned 31,336 shares of the company’s stock after buying an additional 4,035 shares during the period. Johnson & Johnson comprises approximately 1.7% of Family Management Corp’s holdings, making the stock its 13th biggest position. Family Management Corp’s holdings in Johnson & Johnson were worth $4,364,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also bought and sold shares of the company. Virtus ETF Advisers LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $25,000. Krane Funds Advisors LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $26,000. Crewe Advisors LLC lifted its stake in Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after purchasing an additional 196 shares in the last quarter. Permanens Capital L.P. lifted its stake in Johnson & Johnson by 50.0% in the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Thor Advisors LLC purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $69,000. Hedge funds and other institutional investors own 72.01% of the company’s stock.
JNJ stock opened at $131.46 on Friday. The firm has a market cap of $342.22 billion, a PE ratio of 16.07, a PEG ratio of 2.19 and a beta of 0.68. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm’s 50 day moving average price is $130.02 and its 200-day moving average price is $135.75. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.10 EPS. Equities research analysts predict that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were given a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a dividend yield of 2.89%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s payout ratio is presently 46.45%.
JNJ has been the topic of a number of research reports. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Credit Suisse Group set a $156.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Morgan Stanley reissued an “equal weight” rating and issued a $145.00 target price on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research note on Thursday, July 18th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $150.60.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Benefits of owning preferred stock
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.